Last update 23 Jan 2025

Kyowa Kirin Holdings BV

Subsidiary Company|
Netherlands

Overview

Tags

Other Diseases
Congenital Disorders
Immune System Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Neoplasms1
Top 5 Drug TypeCount
Monoclonal antibody2
Top 5 TargetCount
CCR4(C-C chemokine receptor type 4)1
FGF23(Fibroblast growth factor 23)1

Related

2
Drugs associated with Kyowa Kirin Holdings BV
Burosumab-TWZA
Target
FGF23
Mechanism
FGF23 antagonists
Active Org.
Kyowa Kirin Holdings BV [+4]
Originator Org.
Kyowa Kirin Co., Ltd.Kyowa Kirin Co., Ltd.
Active Indication
FGF23 positive Hypophosphatemia [+4]
Inactive Indication
Chronic Pain [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date19 Feb 2018
Mogamulizumab-KPKC
Target
CCR4
Mechanism
CCR4 antagonists
Active Org.
Kyowa Kirin, Inc. [+5]
Originator Org.
Kyowa Hakko Kirin Pharma, Inc.
Active Indication
Mycosis Fungoides [+7]
Inactive Indication
Advanced Malignant Solid Neoplasm [+16]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date30 Mar 2012
100 Clinical Results associated with Kyowa Kirin Holdings BV
Login to view more data
0 Patents (Medical) associated with Kyowa Kirin Holdings BV
Login to view more data
100 Deals associated with Kyowa Kirin Holdings BV
Login to view more data
100 Translational Medicine associated with Kyowa Kirin Holdings BV
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Burosumab-TWZA
 ( FGF23 )		FGF23 positive Hypophosphatemia
More
Approved
Mogamulizumab-KPKC
 ( CCR4 )		Mycosis Fungoides
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free